Drug1st line
Bortezomib (BDR regimen)
Proteasome inhibitor (with dexamethasone + rituximab)
- Response rate
- ~80-85% (frontline BDR)
- Onset
- Weeks-months
- Route
- SC 1.3mg/m2 (weekly) + dexamethasone + rituximab
- Line
- 1st
- IgM effect
- Significant reduction
- Evidence level
- amber
Evidence summary
Proteasome inhibitor active against plasma cell component of WM. Used in BDR (bortezomib-dexamethasone-rituximab) combination. Effective in both frontline and relapsed settings. Risk of peripheral neuropathy limits use, especially in patients with pre-existing IgM neuropathy. Subcutaneous route reduces neuropathy risk.
Approved indications
Conditions for which Bortezomib (BDR regimen) has regulatory approval (not specific to rare diseases covered here):
Multiple MyelomaMantle Cell Lymphoma
Drug identifiers
| DrugBank | DB00188 ↗ |
| ATC Code | L01XG01 |